Category: Clinical Trial Update Region: North America

GlycoEra Initiates Phase 1a Clinical Trial of IgG4-Selective Protein Degrader GE8820

GlycoEra Initiates Phase 1a Clinical Trial of IgG4-Selective Protein Degrader GE8820

GlycoEra, a biotechnology company focused on precision immunology, has initiated dosing of healthy subjects in a Phase 1a clinical trial of GE8820, its investigational IgG4-selective extracellular protein degrader. GE8820 is the first IgG4-selective extracellular protein degrader to enter clinical development.

The drug candidate is designed to rapidly and selectively remove disease-driving IgG4 antibodies while preserving other protective immunoglobulins. The approach could offer a more targeted treatment strategy for autoimmune diseases, including pemphigus vulgaris (PV), primary membranous nephropathy (pMN) and muscle-specific kinase myasthenia gravis (MuSK MG).

According to Ganesh Kaundinya, Ph.D., Chief Executive Officer of GlycoEra, the initiation of clinical testing marks an important step in demonstrating the potential of the company's platform to selectively eliminate disease-driving proteins.

Phase 1a Trial Design

The Phase 1a study is evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of GE8820 in healthy subjects. The trial includes:

  • Single ascending dose (SAD) evaluations.

  • Planned multiple ascending dose (MAD) evaluations.

  • Intravenous and subcutaneous routes of administration.

The study is intended to assess how quickly and extensively GE8820 reduces IgG4 levels and to generate information that will help guide dose selection for subsequent patient trials.

Preclinical Findings and Development Outlook

In a nonhuman primate study, a single intravenous dose of GE8820 achieved more than 95% depletion of circulating human IgG4, with maximum depletion observed in less than 24 hours after dosing.

GlycoEra noted that IgG4 levels are comparable between healthy subjects and patients with certain IgG4-driven autoimmune diseases. The company therefore expects the Phase 1a study to provide useful insights into the speed and depth of IgG4 reduction.

GlycoEra expects to report Phase 1a data in the first half of 2027. These findings are expected to support planned progression into a Phase 1b trial in patients with pemphigus vulgaris and primary membranous nephropathy.

The planned patient study will evaluate safety, tolerability, pharmacology and early signals of clinical activity.

Target Diseases and Mechanism

GE8820 is being developed for multiple IgG4-driven autoimmune diseases:

  • Pemphigus vulgaris (PV): An autoimmune disease associated with blistering of the skin and mucous membranes.

  • Primary membranous nephropathy (pMN): An autoimmune kidney disease that can affect kidney function.

  • Muscle-specific kinase myasthenia gravis (MuSK MG): A rare autoimmune neuromuscular disorder.

GE8820 uses GlycoEra's proprietary glycoengineering platform and is designed to direct IgG4 antibodies toward the body's natural liver-mediated clearance system. Its intended mechanism is to selectively remove disease-driving IgG4 antibodies while preserving other protective immunoglobulins.

The initiation of the Phase 1a trial marks GlycoEra's entry into clinical development and represents an early step in evaluating selective extracellular protein degradation as a potential precision-immunology approach. GE8820 remains investigational, and its safety and efficacy in patients have not yet been established.

Found this useful? Share it with your team.

Welcome Back Sign in to Continue

Don't Have an Account? Sign Up!
Forgot Password?

Create your Account!

Don't Have an Account? Sign Up!